My Profile

Search abstracts

Lewis Sheiner


2017
Budapest, Hungary



2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
København, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 15 (2006) Abstr 929 [www.page-meeting.org/?abstract=929]


Oral Presentation: Lewis Sheiner Student Session


Emilie Hénin A KPD Model for ordered categorical data: application to toxicity score in colorectal cancer patients treated with capecitabine

Hénin, Emilie(1), Klaas P. Zuideveld (2), Céline Dartois (1), Brigitte Tranchand (1,3), Gilles Freyer (1,4), Pascal Girard (1,5)

(1) EA3738, Faculté de Médecine Lyon-Sud, Oullins, Fance ; (2) F. Hoffman-La Roche Ltd., Basel, Switzerland ; (3) Centre Léon Bérard, Lyon, France ; (4) Service d'Oncologie Médicale, Hôpital Lyon-Sud, Pierre-Bénite, France ; (5) INSERM, Lyon, France

PDF of presentation

Introduction: Capecitabine is an oral fluropyrimidine carbamate, converted to 5-Fluorouracil (5FU) predominantly in tumour tissue, prescribed in the treatment of colorectal and breast cancer. Compared to intravenous fluorouracil plus leucovorin, capecitabine shows an at-least equivalent efficacy in terms of time to disease progression and survival and a better tolerability (1,4). In these studies, the Hand-and-Foot Syndrome (HFS) is the only toxicity more frequent with capecitabine than with 5FU, and in fact is the most frequent toxicity of this treatment. It is characterized by cutaneous toxicity, pain, redness, scaling and shedding of the skin of palms and soles and measured by a score representing its severity, scaling from 0 (none) to 3 (skin changes with pain, interfering with function). For therapeutic drug adjustment or testing different dosage regimen, it would be valuable to have a model predicting those scores given drug exposure; but most of the times drug exposure cannot be derived since those studies do not include PK data. However it is possible, using a KPD like approach (2), to derive such a model in certain circumstances were series of scores are collected on long interval times and number of patients is large.

Objectives: To model the longitudinal toxicity score experienced by patients affected with a colorectal cancer, and treated by an oral cytotoxic agent, capecitabine. This model for ordered categorical data includes the effect of the quantity of drug accumulated throughout the treatment without any pharmacokinetic information, and the score experienced at previous time.

Patients & Data: 1207 patients were randomised in two large phase III studies (1,4), which compared the efficacy and the toxicity of 5FU administered intravenously versus oral capecitabine, as first line treatment of metastatic colorectal cancer. Patients were treated over 32 weeks or until disease progression; in responding patients, treatment duration was up to 48 weeks. The median duration of capecitabine treatment was 146 days. Given treatment interruptions at the end of treatment period for many patients, only the first 30 weeks of treatment were modelized. Since very few occurrences of grade 3 were observed, grades 2 and 3 were grouped to a single category. Therefore 3 different scores (0, 1, and ≥2) were considered into the model. Covariates such as age, sex, height, weight, body surface area and type of cancer were considered. Among the 595 patients in capecitabine arm we randomly selected 400 patients to build the model (“building” data set) while 195 were assigned for model qualification (“qualification” data set).

Methods: The probability of experiencing a score of HFS was modelled with an extension of proportional odds ratio model as proposed by Lewis Sheiner (3). The extensions concerned the use of a KPD model for drug exposure and conditional probabilities (Markov model) on transitions from one score to another. Since no pharmacokinetic information was available in those patients, a drug accumulation in the body and a mono-exponential elimination were assumed, which is the principle of the KPD model (2). The parameters of the model were estimated by the Laplacian method implemented in NONMEM software. In the model building process, predictive checks guided the choice of best model as follows: confidence intervals of time-dependant predicted probabilities were compared to observed probabilities. Predicted probabilities were computed by simulating the HFS scores in 100 new building datasets using a degenerate posterior distribution (5).
Once the final model was established, it was qualified by predictive check. We simulated 500 times the toxicity profiles from qualification data set, using the model and likelihood estimates obtained from the building data set. Comparisons were performed between the distribution of number of transitions from one grade to another computed in each simulated data set, and the observed one in the qualification data set.

Results:
Model specification: The final model was a longitudinal proportional odds ratio model with KPD and Markovian component, ie the probability of experiencing a HFS grade was related to the amount of capecitabine administered and to the HFS grade experienced the week before. Tests for covariates effect were performed, and only AGE was significant. Final model is:

Logit{P(Y = 0)}  =  B0 -   EMAX * (Q*K)
(Q*K) + ED50
  + θAGE*(AGE-64) + ηi

Logit{P(Y ≤ 1)}  =  B0 + B1 -   EMAX * (Q*K)
(Q*K) + ED50
  + θAGE*(AGE-64) + ηi

P(Y = 2)  =  1 - P(Y ≤ 1)

where
  • Q is the accumulated dose with an elimination rate constant K (mono-exponential elimination);
  • B0 and B1 > 0 are the logit intercepts for ordered model;
  • EMAX and ED50 are the maximum effect and apparent dose producing 50% decrease of Emax;
  • (AGE-64) is the difference of the AGE with the population median age;
  • ηi, ηK are inter-individual variabilities on logit and K.
  • the parameters B0, B1 and EMAX are dependent of the score at the previous time, which introduces the Markov assumption.

Model qualification: The model constructed on building data set was used to simulate 500 times the HFS profiles of patients in the qualification data set. Predictive check has been performed and the observed probabilities were found to be within the 90% CI obtained from simulations. Also, the number of transitions from one grade to another was compared to the number of transitions observed in the original data set. The observed values from the qualification data set are all included in the interval defined by the quantiles 5% and 95% of the simulated distribution. The distributions (from the simulated sets) of the number of days the patients spend in one given grade were compared to the observed distribution. Based on those simulations the model was accepted.

Conclusions: A longitudinal dose-effect model including a Markov and KPD components from real toxicity longitudinal data was built. The model was  qualified by data splitting using a predictive check and qualification criteria. Future use of the model will be firstly developing individual optimal dosing regimen and secondly assessing the impact of non-compliance on HFS. As long as no patient compliance data is available in the case of treatment of cancer by an oral cytotoxic chemotherapy, an in silico study of non-compliance will be performed in order to quantify its impact on the Hand-and-Foot syndrome.

References:
1. Hoff, P. M., Ansari, R., Batist, G., Cox, J. et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol, 2001; 19(8):2282-2292.
2. Jacqmin, P., Gieschke, R., Jordan, P., Steimer, J-L, Goggin T., Pillai C., Snoeck E., Girard P. Modeling drug induced changes in biomarkers without using drug concentrations: Introducing the K-PD model. PAGE 10 (2001) Abstr 232 [www.page-meeting.org/?abstract=232].
3. Sheiner, L. B. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther, 1994; 56(3):309-322.
4. VanCutsem, E., Twelves, C., Cassidy, J., Allman, D. et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol, 2001; 19(21):4097-4106.
5. Yano Y., Beal S.L., Sheiner L.B. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J.Pharmacokinet.Pharmacodyn. 28 (2):171-192, 2001.